The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...

The company formerly known as Athletic Greens is expanding its market beyond the self-optimizers that follow the podcasters ...

Google Deepmind co-founder Demis Hassabis talks to FT editor Roula Khalaf about the real world healthcare applications of AI and how his ground-breaking work on the structure of proteins could acceler ...

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... However, Cramer also acknowledged that, ...

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...

Eli Lilly announced preliminary ... inventories (wholesaler stocking) for diabetes drug Mounjaro and obesity drug Zepbound. Why it matters: Lilly's growth prospects are driven by Mounjaro and ...